

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/770,382	02/02/2004	Marcel Patek	FRAV2003/0002 US NP	9991
5487	7590 03/20/2006		EXAMINER	
ROSS J. OEHLER			RAO, DEEPAK R	
AVENTIS PHARMACEUTICALS INC. 1041 ROUTE 202-206			ART UNIT	PAPER NUMBER
MAIL CODE: D303A			1624	
BRIDGEWATER, NJ 08807			DATE MAILED: 03/20/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application No.	Applicant(s)		
		10/770,382	PATEK ET AL.		
		Examiner	Art Unit		
		Deepak Rao	1624		
Period fo	The MAILING DATE of this communication a r Reply	ppears on the cover sheet with the	correspondence address		
WHIC - Exter after - If NO - Failu Any r	CRTENED STATUTORY PERIOD FOR REPERIOR IS LONGER, FROM THE MAILING INSIDE OF THE OF THE MAILING INSIDE OF THE	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be to will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	N. imely filed in the mailing date of this communication. ED (35 U.S.C. § 133).		
Status					
2a) <u>□</u> 3) <u>□</u>	Responsive to communication(s) filed on <u>02</u> This action is FINAL . 2b) The Since this application is in condition for allow closed in accordance with the practice under	nis action is non-final. vance except for formal matters, p			
Dispositi	on of Claims				
5) 6) 7)	Claim(s) 1-75 Are pending in the application 4a) Of the above claim(s) is/are withdred Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-75 are subject to restriction and/o	awn from consideration.			
Applicati	on Papers				
10)	The specification is objected to by the Examir The drawing(s) filed on is/are: a) acception acception and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct the oath or declaration is objected to by the Example 1.	ccepted or b) objected to by the e drawing(s) be held in abeyance. Section is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).		
Priority u	nder 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment	c(s) e of References Cited (PTO-892)	4) ☐ Interview Summar	v (PTO-413)		
2) 🔲 Notice 3) 🔲 Inform	e of Nederleffices Cited (P10-692) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/06 No(s)/Mail Date	Paper No(s)/Mail [

DETAILED ACTION

Claims 1-75 are pending in this application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9, 12-50, 52-58 and 61-75, drawn to compounds of formula I wherein p is 0; and R2 and R3 are independent substituents and are NOT taken together to form a cyclic group, corresponding composition and method of use, classified in class 548, subclass various.
- II. Claims 1-8, 10, 12-50, 59 and 62-75, drawn to compounds of formula I wherein p is 1; and R2 and R3 are independent substituents and are NOT taken together to form a cyclic group, corresponding composition and method of use, classified in class 544, subclass various.
- III. Claims 1-8, 11-50 and 62-75, drawn to compounds of formula I wherein **p is 2**; and R2 and R3 are independent substituents and are NOT taken together to form a cyclic group, corresponding composition and method of use, classified in class 540, subclass various.
- IV. Claims 1-9, 12-58 and 61-75, drawn to compounds of formula I wherein **p is 0**; and R2 and R3 taken together form a cyclic group (i.e., spiro compounds), corresponding composition and method of use, classified in class 548, subclass 300.7.

V. Claims 1-8, 10, 12-51, 59-60 and 62-75, drawn to compounds of formula I wherein p is 1; and R2 and R3 taken together form a cyclic group (i.e., spiro compounds), corresponding composition and method of use, classified in class 544, subclass 230.

VI. Claims 1-8, 11-51 and 62-75, drawn to compounds of formula I wherein **p is 2**; and R2 and R3 taken together form a cyclic group (i.e., spiro compounds), corresponding composition and method of use, classified in class 540, subclass 543.

The inventions are distinct, each from the other because of the following reasons:

The compounds of Groups I-VI are drawn to structurally dissimilar compounds. They are made independently and used independently. They would be expected to raise different issues of patentability if a compound of Group I was anticipated, the anticipatory reference would not necessarily render obvious a compound of groups II-VI or vice-versa. They are not art-recognized equivalents, they are separately classified and require separate burdensome searches both in the literature and computer databases.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Claims 1-75 are generic to the following disclosed patentably distinct species comprising the compounds of examples disclosed in the specification. In addition to the election of a single group from above, applicant is required under 35 U.S.C. 121 to elect a single disclosed species falling within the elected group, even though this requirement is traversed.

The species are independent or distinct because the compounds are structurally dissimilar such that a reference anticipating a compound may not render the remaining compounds obvious. 37 CFR 1.141(a) provides that two or more independent and distinct inventions may not be claimed in one application, whether or not the misjoinder occurred in one claim or more than one claim. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deepak Rao whose telephone number is (571) 272-0672. The examiner can normally be reached on Tuesday-Friday from 6:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson, can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

Application/Control Number: 10/770,382 Page 6

Art Unit: 1624

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Deepak Rao Primary Examiner Art Unit 1624

March 16, 2006